RxDoctor Payments DataLook up a doctor →

Paul le, MD

Interventional Pain Medicine · Austin, TXNPI 1770766313

Payments from drug & device makers

$26,511in general payments, 2019–2025

Across 1,009 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$14K
  • Boston Scientific$5K
  • Medtronic$2K
  • AbbVie$773
  • Collegium Pharmaceutical, Inc.$614
  • Nalu Medical, Inc.$496
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$3291%
  • Food & beverage$26,14199%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,511 in reported general payments places this provider in the 80th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$319,977
Medicare patients
559
Services billed
3,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,872$89,372
Xtampza ErOxycodone Myristate101$64,743
OxycontinOxycodone Hcl94$41,314
PercocetOxycodone Hcl/Acetaminophen12$39,790
BelbucaBuprenorphine Hcl57$38,580
Buprenorphine87$30,030
Morphine Sulfate ErMorphine Sulfate527$22,915
NucyntaTapentadol Hcl29$19,648
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen633$14,119
Nucynta ErTapentadol Hcl13$11,497
Oxycodone Hcl617$9,969
Fentanyl103$8,964
MovantikNaloxegol Oxalate16$6,850
LinzessLinaclotide11$5,780
Hydromorphone Hcl295$4,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta, Nucynta Er$614$134,468200 claims
Redhill Biopharma Inc.Movantik$89$6,85016 claims
AbbVieLinzess$773$5,78011 claims
Upsher-smith Laboratories LLCTopiramate$100$15022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →